Exact Sciences Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Exact Sciences Corp.
Guardant Health Launches New Firsts: Blood Test To Track Patient’s Response To Immunotherapy, Tissue-Based Test
Guardant’s launch of a new test to track patient’s response to immunotherapy or targeted drugs and new pan-cancer tissue test, brings it closer to “one-stop-shop” in cancer care continuum.
John Leppard with Washington Analysis says the Medicare agency’s recent delay of the MCIT breakthrough devices rule until mid-December suggests the CMS will likely scrap it altogether and start from scratch.
The SPAC deal between CM Life Sciences II and SomaLogic is valued at $1.25bn.
Lucid, which markets the EsoGuard test for Barrett’s esophagus, will become a separate public company, either through an IPO or a business combination with a health care SPAC.
- Laboratory Testing Services
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- Base Genomics
- Genomic Health, Inc.
- Paradigm Diagnostics, Inc.
- Thrive Earlier Detection Corp.
- Viomics, Inc.